Evidence map›Paper›PMID 26296101›Full record

ReviewExpert opinion on drug discovery2015

Focusing on shared subpockets - new developments in fragment-based drug discovery.

Eman M M Abdelraheem, Carlos J Camacho, Alexander Dömling

Abstract readReview
In one paragraph

Review in Expert opinion on drug discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eman M M Abdelraheema 1 University of Groningen, A. Deusinglaan, Department of Drug Design, 1, Groningen 9700 AD, The Netherlands a.s.s.domling@rug.nl.
Carlos J Camachoc 3 University of Pittsburgh, Department of Computational Biology, School of Medicine , 3501 Fifth Avenue, Suite 3064, Biomedical Science Tower 3 (BST3), Pittsburgh, PA 15260, USA.
Alexander Dömlinga 1 University of Groningen, A. Deusinglaan, Department of Drug Design, 1, Groningen 9700 AD, The Netherlands a.s.s.domling@rug.nl.

Funding

Real-time discovery of inhibitors among billion compounds for preview and downloadR01GM097082 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CAMACHO, CARLOS J. · 2011 to 2020
$2.5M
NIGMS NIH HHS 1R01GM097082-01NIGMS NIH HHS R01 GM097082
6 · The paper itself

Abstract

introductionProtein-protein interactions (PPIs) are important targets for understanding fundamental biology and for the development of therapeutic agents. Based on different physicochemical properties, numerous pieces of software (e.g., POCKETQUERY, ANCHORQUERY and FTMap) have been reported to find pockets on protein surfaces and have applications in facilitating the design and discovery of small-molecular-weight compounds that bind to these pockets. AREAS COVERED: The authors discuss a pocket-centric method of analyzing PPI interfaces, which prioritize their pockets for small-molecule drug discovery and the importance of multicomponent reaction chemistry as starting points for undruggable targets. The authors also provide their perspectives on the field. EXPERT OPINION: Only the tight interplay of efficient computational methods capable of screening a large chemical space and fast synthetic chemistry will lead to progress in the rational design of PPI antagonists in the future. Early drug discovery platforms will also benefit from efficient rapid feedback loops from early clinical research back to molecular design and the medicinal chemistry bench.

Indexed as

Drug DesignChemistry, PharmaceuticalDrug DiscoveryHumansProtein BindingProteinsSoftwareProteinsAnchorANCHORQUERYchemical spacemulticomponent reactionpocket clusterPOCKETQUERYprotein–protein interactionsvirtual screening

Identifiers

PMID26296101
PMCPMC4933841

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.